Conference Coverage
Conference Coverage
Repeat VTE risk heightened in HIV patients
SEATTLE – Two studies detail the risk factors of first-time venous thromboembolism and heightened incidence of repeat VTE in patients with HIV.
Conference Coverage
MRD status at transplant predicts outcomes in ALL patients
HOUSTON – Acute lymphoblastic leukemia patients with measurable residual disease (MRD) negativity prior to...
Conference Coverage
Secondary AML in first remission predicts outcomes
HOUSTON – Secondary AML predicts outcomes after SCT in first complete remission, whereas factors such as age, cytogenetics, and performance status...
Conference Coverage
Haplo-HSCT bests chemotherapy for MRD-positive adult ALL
HOUSTON – Haplo-HSCT outperforms chemotherapy for the treatment of adults with ALL in first complete response, particularly MRD-positive patients...
Conference Coverage
Therapeutic dosing of busulfan helps reduce relapse in ASCT
HOUSTON - Pharmacokinetic-directed therapeutic dose monitoring of busulfan used in combination with cyclophosphamide and etoposide appears to...
Conference Coverage
Anti-CD45 conditioning looks safe, feasible in relapsed AML
HOUSTON – Iomab-B use has resulted in successful engraftment for all patients who have received it and gone on to transplant, despite active...
Conference Coverage
Novel immunostimulant combo shows early efficacy
SAN FRANCISCO – A one-two approach to stimulating both innate and adaptive immunity appears to be paying off, suggest early efficacy data from a...
Conference Coverage
MI, strokes spike during 30 days after cancer diagnosis
HONOLULU – During the first 30 days after a cancer diagnosis, the incidence of an MI or stroke jumped nearly 500%.
Conference Coverage
Antibiotics gut checkpoint inhibitor efficacy
SAN FRANCISCO – Patients who had received antibiotics more than a month before a checkpoint inhibitor had significantly worse survival, regardless...
Conference Coverage
Pembrolizumab/lenvatinib active against urothelial carcinoma
SAN FRANCISCO – Early objective responses were sufficient to prompt a larger phase 3 trial of the TKI and immune checkpoint inhibitor combination...
Conference Coverage
Higher dose of checkpoint inhibitor every 4 weeks feasible in NSCLC
SAN FRANCISCO – The 6-month PFS rates were similar for patients treated every 2 or 4 weeks, but the trial could not show noninferiority of...